Myelodysplastic Syndrome with Isolated del(5q)
Associated Genetic Biomarkers
NCI Definition: A myelodysplastic syndrome characterized by a deletion between bands q31 and 33 on chromosome 5. The number of blasts in the bone marrow and blood is <5%. The bone marrow is usually hypercellular or normocellular with increased number of often hypolobated megakaryocytes. The peripheral blood shows macrocytic anemia. This syndrome occurs predominantly but not exclusively in middle age to older women. The prognosis is good and transformation to acute leukemia is rare. (WHO, 2001) 
There are 3 clinical trials for myelodysplastic syndrome with isolated del(5q), of which 3 are open and 0 are completed or closed. Of the trials that contain myelodysplastic syndrome with isolated del(5q) as an inclusion criterion, 1 is early phase 1 (1 open) and 2 are phase 2 (2 open).
Allogeneic hematopoietic stem cell transplantation, azacitidine, and cyclophosphamide are the most common interventions in myelodysplastic syndrome with isolated del(5q) clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.